

DAFTAR PUSTAKA

- Adrian M. Di Bisceglie, M. (2002). Epidemiology and Clinical Presentation of Hepatocellular Carcinoma. *J Vasc Interv Radiol* 2002, 13, 169–171.
- Augusto Villanueva, M.D., P. . (2019). Hepatocellular Carcinoma. *The New England Journal of Medicine*, 15(380), 1450–62. <https://doi.org/10.1056/NEJMra1713263>
- Balogh, J., Iii, D. V., Gordon, S., Li, X., Ghobrial, R. M., & Jr, H. P. M. (2016). Jhc-3-041. *Journal of Hepatocellular Carcinoma*, Volume 3, 41–53.
- Bangun, A. (2022). *Perbandingan Respon Terapi Transarterial Chemoembolization pada Karsinoma Hepatoseluler antara Kriteria Modified dan Volumetric Recist pada CT Scan*. Diambil dari <https://etd.repository.ugm.ac.id/penelitian/detail/216498>
- Choi, J., Lee, D., Shim, J. H., Kim, K. M., Lim, Y. S., Lee, Y. S., & Lee, H. C. (2020). Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma. *PLoS ONE*, 15(3), 1–13. <https://doi.org/10.1371/journal.pone.0229696>
- Dasgupta, P., Henshaw, C., Youlden, D. R., Clark, P. J., Aitken, J. F., & Baade, P. D. (2020). Global Trends in Incidence Rates of Primary Adult Liver Cancers: A Systematic Review and Meta-Analysis. *Frontiers in Oncology*, 10(February), 1–17. <https://doi.org/10.3389/fonc.2020.00171>
- Delli Pizzi, A., Mastrodicasa, D., Cianci, R., Serafini, F. L., Mincuzzi, E., Di Fabio, F., ... Caulo, M. (2021). Multimodality Imaging of Hepatocellular Carcinoma: From Diagnosis to Treatment Response Assessment in Everyday Clinical Practice. *Canadian Association of Radiologists Journal*, 72(4). <https://doi.org/10.1177/0846537120923982>
- Elsayes, K. M., Kielar, A. Z., Chernyak, V., Morshid, A., Furlan, A., Masch, W. R., ... Sirlin, C. B. (2019). <p>LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance</p>. *Journal of Hepatocellular Carcinoma*, Volume 6, 49–69. <https://doi.org/10.2147/jhc.s186239>
- Forner, A., Reig, M., & Bruix, J. (2018). Hepatocellular carcinoma. *The Lancet*, 391(10127), 1301–1314. [https://doi.org/10.1016/S0140-6736\(18\)30010-2](https://doi.org/10.1016/S0140-6736(18)30010-2)
- Georgiades, C., Geschwind, J. F., Harrison, N., Hines-Peralta, A., Liapi, E., Hong, K., ... Frangakis, C. (2012). Lack of response after initial chemoembolization for hepatocellular carcinoma: Does it predict failure of subsequent treatment? *Radiology*, 265(1). <https://doi.org/10.1148/radiol.12112264>

- Gregory, J., Dioguardi Burgio, M., Corrias, G., Vilgrain, V., & Ronot, M. (2020). Evaluation of liver tumour response by imaging. *JHEP Reports*, 2(3), 100100. <https://doi.org/10.1016/j.jhepr.2020.100100>
- Hajkova, M., Andrasina, T., Ovesna, P., Rohan, T., Dostal, M., Valek, V., ... Kiss, I. (2022). Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization and its Impact on Overall Survival. *In Vivo*, 36(5). <https://doi.org/10.21873/invivo.12964>
- Hayano, K., Lee, S. H., & Sahani, D. V. (2015). Imaging for assessment of treatment response in hepatocellular carcinoma: Current update. *Indian Journal of Radiology and Imaging*, 25(2), 121–128. <https://doi.org/10.4103/0971-3026.155835>
- Katherine A. McGlynn, Jessica L. Petrick, H. B. E.-S. (2021). Epidemiology of the hepatocellular carcinoma. *Epidemiology of Hepatocellular Carcinoma*, 73(Suppl 1), : 4–13. <https://doi.org/10.3109/9780203092880-4>
- Kementerian Kesehatan RI. (2018). *Riset Kesehatan Dasar Tahun 2018*. Diambil dari <http://labdata.litbang.depkes.go.id/riset-badan-litbangkes/menu-risikesnas/menu-risikesdas>
- Kloeckner, R., Galle, P. R., & Bruix, J. (2021). Local and Regional Therapies for Hepatocellular Carcinoma. *Hepatology*. <https://doi.org/10.1002/hep.31424>
- Lee, S. W., Yen, C. L., Cheng, Y. C., Shun Yang, S., & Lee, T. Y. (2022). The radiological prognostic factors of transcatheter arterial chemoembolization to hepatocellular carcinoma. *Medicine (United States)*, 101(41). <https://doi.org/10.1097/MD.00000000000030875>
- Lim, M. C., Tan, C. H., Cai, J., Zheng, J., & Kow, A. W. C. (2014). CT volumetry of the liver: Where does it stand in clinical practice? *Clinical Radiology*, 69(9), 887–895. <https://doi.org/10.1016/j.crad.2013.12.021>
- Lior Charach, Lior Zusmanovitch, *Gideon Charach. (2017). HEPATOCELLULAR CARCINOMA. PART 2: CLINICAL PRESENTATION AND DIAGNOSIS. *EUROPEAN MEDICAL JOURNAL*, 5, 81-88.
- Liu, C., Wu, J., & Chang, Z. (2021). Trends and age-period-cohort effects on the prevalence, incidence and mortality of hepatocellular carcinoma from 2008 to 2017 in Tianjin, China. *International Journal of Environmental Research and Public Health*, 18(11). <https://doi.org/10.3390/ijerph18116034>
- Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., ... Finn, R. S. (2021). Hepatocellular carcinoma. *Nature Reviews Disease Primers*, 7(1). <https://doi.org/10.1038/s41572-020-00240-3>
- Mahadevan, V. (2020). Anatomy of the liver. *Surgery (United Kingdom)*, 38(8), 427–431. <https://doi.org/10.1016/j.mpsur.2014.10.004>

- Manitz, J., D'Angelo, S. P., Apolo, A. B., Eggleton, S. P., Bajars, M., Bohnsack, O., & Gulley, J. L. (2022). Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival. *Journal for ImmunoTherapy of Cancer*, 10(2). <https://doi.org/10.1136/jitc-2021-003302>
- McGlynn, K. A., Petrick, J. L., & El-Serag, H. B. (2021). Epidemiology of Hepatocellular Carcinoma. *Hepatology*, 73(S1), 4–13. <https://doi.org/10.1002/hep.31288>
- Moawad, A. W., Fuentes, D., Khalaf, A. M., Blair, K. J., Szklaruk, J., Qayyum, A., ... Elsayes, K. M. (2020). Feasibility of Automated Volumetric Assessment of Large Hepatocellular Carcinomas' Responses to Transarterial Chemoembolization. *Frontiers in Oncology*, 10. <https://doi.org/10.3389/fonc.2020.00572>
- Müller, L., Stoehr, F., Mähringer-Kunz, A., Hahn, F., Weinmann, A., & Kloeckner, R. (2021). Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. *Journal of Hepatocellular Carcinoma*, Volume 8. <https://doi.org/10.2147/jhc.s285735>
- Narsinh, K. H., Duncan, D. P., Newton, I. G., Minocha, J., & Rose, S. C. (2018). Liver-directed therapy for hepatocellular carcinoma. *Abdominal Radiology*, 43(1), 203–217. <https://doi.org/10.1007/s00261-017-1435-6>
- Nataria, E. (2018). *Evaluasi Respon Tumor Menurut Recist 1.1 Dan Modified Recist Pada Pasien Karsinoma Hepatoseluler Setelah Tace*. Yogyakarta.
- Nishioka, Y., & Shindoh, J. (2022). Liver Anatomy. *Colorectal Liver Metastasis*. https://doi.org/10.1007/978-3-031-09323-4_2
- Osman, M. F., Farag, A. S. A., Samy, H. A., El-Baz, T. M., & Elkholy, S. F. (2021). Role of multislice computed tomography 3D volumetric analysis in the assessment of the therapeutic response of hepatocellular carcinoma after transarterial chemoembolization. *Egyptian Journal of Radiology and Nuclear Medicine*, 52(1). <https://doi.org/10.1186/s43055-021-00542-w>
- Piscaglia, F., & Ogasawara, S. (2018). Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment. *Liver Cancer*. <https://doi.org/10.1159/000485471>
- Santillan, C. (2020). CT and MRI of the liver for hepatocellular carcinoma. *Hepatoma Research*, 2020. <https://doi.org/10.20517/2394-5079.2020.60>
- Shah, S., Shukla, A., & Paunipagar, B. (2014). Radiological Features of Hepatocellular Carcinoma. *Journal of Clinical and Experimental Hepatology*, 4(August), S63–S66. <https://doi.org/10.1016/j.jceh.2014.06.009>
- Tacher, V., Lin, M. De, Duran, R., Yarmohammadi, H., Lee, H., Chapiro, J., ... Geschwind, J. F. (2016). Comparison of existing response criteria in patients with hepatocellular carcinoma treated with transarterial chemoembolization

using a 3D quantitative approach. *Radiology*, 278(1).
<https://doi.org/10.1148/radiol.2015142951>

Timaran Montenegro, D. E., Torres Ramirez, C. A., Mateo C, Y. S., Govea Palma, J., Quiñones, J. C., & Orozco Vazquez, J. S. (2020). CT-Based Hepatic Residual Volume and Predictors of Outcomes of Patients with Hepatocellular Carcinoma Unsuitable for Surgical Therapy Undergoing Transarterial Chemoembolization. *Academic Radiology*, 27(6), 807–814.
<https://doi.org/10.1016/j.acra.2019.09.003>

Vernon, H., Wehrle, C. J., Alia, V. S. K., & Kasi, A. (2022). Anatomy, Abdomen and Pelvis, Liver - StatPearls - NCBI Bookshelf.

Vietti Violi, N., Lewis, S., Hectors, S., Said, D., & Taouli, B. (2019). Radiological Diagnosis and Characterization of HCC, 71–92. https://doi.org/10.1007/978-3-030-21540-8_4

West, H., & Jin, J. O. (2015). Transarterial chemoembolization. *JAMA Oncology*, 1(8), 1178. <https://doi.org/10.1001/jamaoncol.2015.3702>

Yu, H., Bai, Y., Xie, X., Feng, Y., Yang, Y., & Zhu, Q. (2022). RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis. *BMJ open*, 12(6). <https://doi.org/10.1136/bmjopen-2021-052294>

Zheng, R., Qu, C., Shang, S., & Zeng, H. (2018). Liver cancer incidence and mortality in China: Temporal trends and projections to 2030. *Chin J Cancer Res*, 30(6), 571–579. <https://doi.org/10.21147/j.issn.1000-9604.2018.06.01>

Zhu, R. X., Seto, W. K., Lai, C. L., & Yuen, M. F. (2016). Epidemiology of hepatocellular carcinoma in the Asia-Pacific region. *Gut and Liver*, 10(3), 332–339. <https://doi.org/10.5009/gnl15257>